Reviva Pharmaceuticals Ownership
| RVPH Stock | USD 1.84 0.05 2.79% |
Shares in Circulation | First Issued 2018-06-30 | Previous Quarter 30.6 M | Current Value 33.8 M | Avarage Shares Outstanding 14 M | Quarterly Volatility 10.7 M |
Reviva |
Reviva Stock Ownership Analysis
About 15.0% of the company outstanding shares are owned by corporate insiders. The company recorded a loss per share of 1.08. Reviva Pharmaceuticals had not issued any dividends in recent years. Reviva Pharmaceuticals Holdings, Inc., a clinical-stage biopharmaceutical company, discovers, develops, and commercializes next-generation therapeutics for diseases targeting unmet medical needs in the areas of central nervous system, respiratory, cardiovascular, metabolic, and inflammatory diseases. It is also developing RP1208 that is in pre-clinical development studies for the treatment of depression and obesity. Reviva Pharmaceuticals operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 5 people. To find out more about Reviva Pharmaceuticals Holdings contact Laxminarayan Bhat at 408-501-8881 or learn more at https://www.revivapharma.com.Besides selling stocks to institutional investors, Reviva Pharmaceuticals also allocates a substantial amount of its earnings to a pull of share-based compensation to be paid out to its employees, managers, executives, and members of the board of directors. Share-Based compensation (also sometimes called Stock-Based Compensation) is a way of paying different Reviva Pharmaceuticals' stakeholders with equity in the business. It is typically used as a motivation factor for employees to contribute beyond their regular compensation (salary and bonus). It is also used as a tool to align Reviva Pharmaceuticals' strategic interests with those of the company's shareholders. Shares issued to employees are usually subject to a vesting period before they are earned and sold.
Reviva Pharmaceuticals Quarterly Liabilities And Stockholders Equity |
|
About 15.0% of Reviva Pharmaceuticals Holdings are currently held by insiders. Unlike Reviva Pharmaceuticals' institutional investors, corporate insiders most likely have a limit on the maximum percentage of share ownership. This is done to align insiders' influence against Reviva Pharmaceuticals' private investors even though both sides will benefit from rising prices or experience loss when the share price declines. The good rule to have in mind is that the maximum share ownership percentage of the corporate insiders should not surpass 25%. View all of Reviva Pharmaceuticals' insider trades
Reviva Stock Institutional Investors
Have you ever been surprised when a price of an equity instrument such as Reviva Pharmaceuticals is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading Reviva Pharmaceuticals Holdings backward and forwards among themselves. Reviva Pharmaceuticals' institutional investor refers to the entity that pools money to purchase Reviva Pharmaceuticals' securities or originate loans. Institutional investors include commercial and private banks, credit unions, insurance companies, pension funds, hedge funds, endowments, and mutual funds. Operating companies that invest excess capital in these types of assets may also be included in the term and may influence corporate governance by exercising voting rights in their investments.
| Shares | State Street Corp | 2024-09-30 | 71.4 K | Susquehanna International Group, Llp | 2024-09-30 | 63.2 K | H D Vest Advisory Services | 2024-09-30 | 60 K | Northern Trust Corp | 2024-09-30 | 57.7 K | Sound Income Strategies | 2024-09-30 | 30 K | Two Sigma Investments Llc | 2024-09-30 | 21.4 K | Emc Capital Management(tx) | 2024-09-30 | 18.4 K | Virtu Financial Llc | 2024-09-30 | 14.3 K | Two Sigma Securities, Llc | 2024-09-30 | 13.9 K | Armistice Capital, Llc | 2024-09-30 | 3.2 M | Millennium Management Llc | 2024-09-30 | 1.8 M |
Reviva Pharmaceuticals Insider Trading Activities
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Reviva Pharmaceuticals insiders, such as employees or executives, is commonly permitted as long as it does not rely on Reviva Pharmaceuticals' material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases Reviva Pharmaceuticals insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Reviva Pharmaceuticals Outstanding Bonds
Reviva Pharmaceuticals issues bonds to finance its operations. Corporate bonds make up one of the largest components of the U.S. bond market, which is considered the world's largest securities market. Reviva Pharmaceuticals uses the proceeds from bond sales for a wide variety of purposes, including financing ongoing mergers and acquisitions, buying new equipment, investing in research and development, buying back their own stock, paying dividends to shareholders, and even refinancing existing debt. Most Reviva bonds can be classified according to their maturity, which is the date when Reviva Pharmaceuticals Holdings has to pay back the principal to investors. Maturities can be short-term, medium-term, or long-term (more than ten years). Longer-term bonds usually offer higher interest rates but may entail additional risks.
Currently Active Assets on Macroaxis
When determining whether Reviva Pharmaceuticals is a strong investment it is important to analyze Reviva Pharmaceuticals' competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact Reviva Pharmaceuticals' future performance. For an informed investment choice regarding Reviva Stock, refer to the following important reports:Check out Your Equity Center to better understand how to build diversified portfolios, which includes a position in Reviva Pharmaceuticals Holdings. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in american community survey. You can also try the Instant Ratings module to determine any equity ratings based on digital recommendations. Macroaxis instant equity ratings are based on combination of fundamental analysis and risk-adjusted market performance.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Reviva Pharmaceuticals. If investors know Reviva will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Reviva Pharmaceuticals listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
The market value of Reviva Pharmaceuticals is measured differently than its book value, which is the value of Reviva that is recorded on the company's balance sheet. Investors also form their own opinion of Reviva Pharmaceuticals' value that differs from its market value or its book value, called intrinsic value, which is Reviva Pharmaceuticals' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Reviva Pharmaceuticals' market value can be influenced by many factors that don't directly affect Reviva Pharmaceuticals' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Reviva Pharmaceuticals' value and its price as these two are different measures arrived at by different means. Investors typically determine if Reviva Pharmaceuticals is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Reviva Pharmaceuticals' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.